Preimplantation Genetic Diagnosis Market By Procedure Type (IVF with PGD, IVF with PGS), By Application (Genetic Disorder Screening, Gender Selection, Inherited Disease Screening), By End-User (Fertility Clinics, Hospitals, Diagnostic Laboratories), By Technology (Microarray-Based PGD, Next-Generation Sequencing, Fluorescence in situ Hybridization (FISH), PCR-Based PGD), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Preimplantation Genetic Diagnosis Market was valued at USD 4.8 billion in 2024-e and will surpass USD 8.3 billion by 2030; growing at a CAGR of 9.6% during 2025 - 2030.

The global preimplantation genetic diagnosis (PGD) market is experiencing steady growth, driven by advances in assisted reproductive technologies and an increasing demand for genetic screening to prevent inherited diseases. PGD allows for the screening of embryos for specific genetic conditions before implantation during in vitro fertilization (IVF), enabling the selection of embryos free from certain genetic disorders. This has become a critical tool for couples with a history of genetic conditions, as well as those seeking gender selection for family balancing. Growing awareness of PGD’s benefits and increasing accessibility to fertility treatments are major factors influencing market expansion.

Technological advancements in PGD, including the use of next-generation sequencing and microarray-based techniques, are revolutionizing the accuracy and efficiency of genetic testing. These innovations are significantly reducing the risk of genetic disorders in newborns and improving the success rates of IVF procedures. As the prevalence of genetic disorders rises and consumer awareness increases, the demand for PGD procedures is expected to continue its upward trajectory.

IVF with PGD Procedure is Largest Owing to Widespread Use in Genetic Screening

The IVF with PGD procedure is the largest segment in the market, owing to its widespread application in genetic disorder screening and its significant role in improving IVF success rates. This procedure enables the screening of embryos for a wide range of genetic disorders, such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease, among others. It is particularly beneficial for couples with a known genetic predisposition to specific hereditary diseases, as it minimizes the risk of passing these conditions onto their offspring.

The success of IVF with PGD is attributed to its high accuracy in detecting genetic abnormalities, allowing clinicians to select embryos with the best genetic profiles for implantation. This procedure has become a cornerstone of modern fertility treatments and is often offered as a standard service in fertility clinics, contributing to its dominance in the market.

Genetic Disorder Screening is Fastest Growing Owing to Rising Demand for Disease Prevention

The genetic disorder screening application segment is the fastest growing, as an increasing number of prospective parents are opting for PGD to prevent the transmission of genetic diseases. With the rising prevalence of genetic disorders globally and heightened awareness of their impact, more individuals are turning to PGD as a preventive measure during IVF treatments. This application segment primarily focuses on the early detection of disorders like Huntington's disease, hemophilia, and Down syndrome, enabling the selection of genetically healthy embryos.

The demand for genetic disorder screening is also driven by the growing availability of PGD services and advancements in genetic testing technologies, which have made screening more affordable and accurate. As healthcare providers continue to emphasize disease prevention, the genetic disorder screening application is likely to remain a major growth driver in the PGD market.

Fertility Clinics Segment is Largest Owing to High Adoption of Assisted Reproductive Technologies

Fertility clinics represent the largest end-user segment in the PGD market, as they are the primary providers of assisted reproductive technologies, including IVF and PGD. These clinics offer a comprehensive range of fertility services, making them the preferred choice for couples seeking genetic testing to ensure the health of their future children. Fertility clinics are also at the forefront of adopting the latest advancements in PGD technology, thereby enhancing their service offerings and improving patient outcomes.

The growing number of fertility clinics, along with their focus on providing personalized treatments, has led to an increased demand for PGD procedures. These clinics offer a supportive environment for patients undergoing fertility treatments, and the integration of PGD into IVF protocols has become a standard practice in many facilities, further bolstering the segment's dominance.

Next-Generation Sequencing Technology is Fastest Growing Owing to Enhanced Accuracy and Precision

Next-generation sequencing (NGS) technology is the fastest growing in the PGD market, owing to its superior accuracy, sensitivity, and ability to analyze large volumes of genetic data. NGS allows for a more comprehensive analysis of embryos, enabling the detection of a wide range of genetic mutations with greater precision. This technology has revolutionized the field of PGD, offering clinicians the ability to screen embryos for an expanded array of genetic disorders, including rare and complex conditions.

The increasing adoption of NGS in PGD is attributed to its ability to provide high-resolution genetic data, which significantly improves the chances of selecting healthy embryos for implantation. As the technology becomes more widely available and affordable, it is expected to continue driving the growth of the PGD market.

North America is Largest Owing to Advanced Healthcare Infrastructure and High Awareness

North America is the largest region in the preimplantation genetic diagnosis market, driven by its advanced healthcare infrastructure, high fertility clinic density, and strong consumer awareness of genetic testing and assisted reproductive technologies. The United States, in particular, has a well-established market for PGD, with a large number of fertility clinics offering PGD as part of their IVF services. Government policies and insurance coverage for fertility treatments have also played a crucial role in making PGD more accessible to a broader demographic.

In addition, North America’s dominance in the PGD market is supported by the region's strong research and development activities, which continue to lead to technological innovations and improvements in PGD procedures. As a result, North America remains the largest market for PGD, with significant growth potential driven by increasing demand for genetic screening and reproductive health services.

Competitive Landscape

The preimplantation genetic diagnosis market is highly competitive, with several leading companies and fertility clinics vying for market share through innovation, strategic partnerships, and technological advancements. Key players such as Illumina, Thermo Fisher Scientific, and F. Hoffmann-La Roche are at the forefront of developing and providing next-generation sequencing and microarray-based PGD technologies. These companies are investing heavily in research to enhance the precision and affordability of PGD, which is expected to drive further market expansion.

Additionally, fertility clinics such as New Hope Fertility Center and CCRM (Colorado Center for Reproductive Medicine) are leveraging advanced PGD techniques to improve patient outcomes and attract a larger patient base. As the demand for genetic testing and IVF services continues to rise, these companies and clinics will play a pivotal role in shaping the future of the PGD market. The increasing adoption of PGD technologies and the growing number of service providers will continue to fuel the competitive dynamics in this rapidly evolving market.

List of Leading Companies:

• Illumina Inc.
• Thermo Fisher Scientific
• CooperSurgical, Inc.
• Reprogenetics, LLC
• Genea Limited
• Genomic Prediction, Inc.
• NextGen IVF
• Embryo Technologies
• Vitrolife AB
• Ferring Pharmaceuticals
• IntegraGen
• Centre for Human Reproduction
• LabCorp
• EMD Serono
• BIOPSYGEN

Recent Developments:

• In January 2025, Illumina Inc. launched an advanced PGD screening tool that improves genetic disorder detection in embryos.
• In December 2024, Ferring Pharmaceuticals expanded its IVF solutions by including PGD for inherited genetic conditions.
• In November 2024, Vitrolife AB partnered with leading fertility clinics to enhance PGD testing capabilities with next-generation sequencing technology.
• In October 2024, Reprogenetics, LLC introduced a new PGD service that offers comprehensive chromosomal screening for IVF embryos.
• In September 2024, Genea Limited announced the integration of a PCR-based PGD service aimed at improving the detection of rare genetic disorders.

eport Scope: